Preclinical Characterization of Recombinant Human Tissue Kallikrein-1 as a Novel Treatment for Type 2 Diabetes Mellitus

• Tadeusz Kolodka,

  Affiliation DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America

  ⨯
• Matthew L. Charles,

  Affiliation DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America

  ⨯
• Arvind Raghavan ,

  * E-mail: araghavan@diamedica.com

  Affiliation DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America

  ⨯
• Ilian A. Radichev,

  Affiliation Sanford Project/Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America

  ⨯
• Christina Amatya,

  Affiliation Sanford Project/Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America

  ⨯
• Jacob Ellefson,

  Affiliation Sanford Project/Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America

  ⨯
• Alexei Y. Savinov,

  Affiliation Sanford Project/Children’s Health Research Center, Sanford Research, Sioux Falls, South Dakota, United States of America

  ⨯
• Abhijeet Nag,

  Affiliation Invitek, Inc., Hayward, California, United States of America

  ⨯
• Mark S. Williams,

  Affiliation DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America

  ⨯
• Mark S. Robbins

  Affiliation DiaMedica USA, Inc., Minneapolis, Minnesota, United States of America

  ⨯